{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:20:38Z","timestamp":1789572038665,"version":"build-2803163510"},"reference-count":60,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Differentiated thyroid carcinoma (DTC) is the most common malignant endocrine tumor, with a generally favorable prognosis. Imaging, including iodine radioactive isotope scintigraphy (IRIS), is crucial for diagnosis and follow-up. While 131I has long been used for both therapeutic and diagnostic purposes, 123I is reserved for diagnostic imaging due to its shorter half-life and \u03b3 emissions. This review highlights the utility of 123I scintigraphy, especially in pre-treatment assessment and dosimetry for DTC. It is particularly valuable before radioiodine (RAI) ablation, providing accurate imaging in patients with iodine-refractory (IR) or biochemically incomplete response (BIR) DTC. When compared to post-therapeutic 131I scans, 123I scintigraphy appears to have a lower sensitivity for detecting metastatic lesions, particularly in lymph nodes and lungs. However, its diagnostic performance compared to low-dose diagnostic 131I is more variable, with some studies suggesting superiority due to the absence of stunning. Further research is needed to standardize its use and optimize its role in guiding DTC management.<\/jats:p>","DOI":"10.3390\/medsci14010068","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:12:37Z","timestamp":1770048757000},"page":"68","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of 123I in the Management of Differentiated Thyroid Cancer: A Comprehensive Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3599-0492","authenticated-orcid":false,"given":"Pietro","family":"Bellini","sequence":"first","affiliation":[{"name":"Nuclear Medicine, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4839-9033","authenticated-orcid":false,"given":"Francesco","family":"Dondi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, ASST Spedali Civili di Brescia and University of Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8448-2118","authenticated-orcid":false,"given":"Michela","family":"Cossandi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Vigan\u00f2","sequence":"additional","affiliation":[{"name":"Clinical Engineering, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4317-1232","authenticated-orcid":false,"given":"Carlo","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, SSD Endocrinologia, University of Brescia, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-3746","authenticated-orcid":false,"given":"Elisa","family":"Gatta","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, SSD Endocrinologia, University of Brescia, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Otolaryngology Unit, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Morandi","sequence":"additional","affiliation":[{"name":"Surgical Clinic, Universit\u00e0 Degli Studi di Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Casella","sequence":"additional","affiliation":[{"name":"Surgical Clinic, Universit\u00e0 Degli Studi di Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-7411","authenticated-orcid":false,"given":"Luigi","family":"Spiazzi","sequence":"additional","affiliation":[{"name":"Health Physics Department, Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Rodella","sequence":"additional","affiliation":[{"name":"Health Physics Department, Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Saiani","sequence":"additional","affiliation":[{"name":"Health Physics Department, Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ingraito","sequence":"additional","affiliation":[{"name":"Health Physics Department, Spedali Civili, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zilioli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, ASST Spedali Civili di Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, ASST Spedali Civili di Brescia and University of Brescia, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Giovanella, L. (2023). Biomarkers and Molecular Imaging in Postoperative DTC Management. Integrated Diagnostics and Theranostics of Thyroid Diseases, Springer.","DOI":"10.1007\/978-3-031-35213-3"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1210\/clinem\/dgac721","article-title":"Evaluating Disease-specific Survival Prediction of Risk Stratification and TNM Systems in Differentiated Thyroid Cancer","volume":"108","author":"Peeters","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MED.0000000000000359","article-title":"The thyroid cancer epidemic, 2017 perspective","volume":"24","author":"Roman","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s12020-024-03688-5","article-title":"Prognostic role and characteristics of the indeterminate response in differentiated thyroid cancer: A systematic review","volume":"84","author":"Bellini","year":"2024","journal-title":"Endocrine"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Albano, D., Bellini, P., Dondi, F., Calabr\u00f2, A., Casella, C., Taboni, S., Lombardi, D., Treglia, G., and Bertagna, F. (2023). Temporal Evolution and Prognostic Role of Indeterminate Response Sub-Groups in Patients with Differentiated Thyroid Cancer after Initial Therapy with Radioiodine. Cancers, 15.","DOI":"10.3390\/cancers15041270"},{"key":"ref_8","first-page":"170","article-title":"Radioiodine scintigraphy with SPECT\/CT: An important diagnostic tool for thyroid cancer staging and risk stratification","volume":"42","author":"Avram","year":"2014","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12020-016-1086-3","article-title":"Differentiated thyroid carcinoma: Incremental diagnostic value of 131I SPECT\/CT over planar whole body scan after radioiodine therapy","volume":"56","author":"Zilioli","year":"2017","journal-title":"Endocrine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sun, Y.-Q., Sun, D., Zhang, X., Zhang, Y.-Q., and Lin, Y.-S. (2022). Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.994288"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Albano, D., Dondi, F., Mazzoletti, A., Bellini, P., Rodella, C., and Bertagna, F. (2021). Prognostic Role of 2-[18F]FDG PET\/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative 131I WBS and Positive 2-[18F]-FDG PET\/CT. Diagnostics, 11.","DOI":"10.3390\/diagnostics11122189"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.biopha.2006.07.008","article-title":"Role of 18F-FDG-PET and PET\/CT imaging in thyroid cancer","volume":"60","author":"Nanni","year":"2006","journal-title":"Biomed. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.diii.2021.04.004","article-title":"PET\/CT in the management of differentiated thyroid cancer","volume":"102","author":"Zampella","year":"2021","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12020-024-03989-9","article-title":"Diagnostic performance of 2-[18F]FDG PET\/CT in recurrent differentiated thyroid cancer and elevated antithyroglobulin antibodies: An updated systematic review and bivariate meta-analysis","volume":"87","author":"Albano","year":"2025","journal-title":"Endocrine"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bellini, P., Dondi, F., Cappelli, C., Gatta, E., Lombardi, D., Casella, C., Morandi, R., Vigan\u00f2, G., Camoni, L., and Cossandi, M. (2025). The Impact of Radioiodine (131I) Therapy of Thyroid Disease on Salivary Glands Function and Inflammation: A Comprehensive Review. Biomedicines, 13.","DOI":"10.3390\/biomedicines13061404"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Campenn\u00ec, A., Siracusa, M., and Ruggeri, R.M. (2024). Oldie but Goldie: The Fundamental Role of Radioiodine in the Management of Thyroid Cancer. J. Clin. Med., 13.","DOI":"10.3390\/jcm13216400"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.7861\/clinmedicine.17-5-453","article-title":"Molecular radiotheragnostics in thyroid disease","volume":"17","author":"Singh","year":"2017","journal-title":"Clin. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Giovanella, L., Deandreis, D., Vrachimis, A., Campenni, A., and Ovcaricek, P.P. (2022). Molecular Imaging and Theragnostics of Thyroid Cancers. Cancers, 14.","DOI":"10.3390\/cancers14051272"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"245001","DOI":"10.1088\/1361-6560\/ab58fe","article-title":"Primary, scatter, and penetration characterizations of parallel-hole and pinhole collimators for I-123 SPECT","volume":"64","author":"Auer","year":"2019","journal-title":"Phys. Med Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","article-title":"EANM Dosimetry Committee. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: Blood and bone marrow dosimetry in differentiated thyroid cancer therapy","volume":"35","author":"Lassmann","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1677\/ERC-09-0076","article-title":"Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma","volume":"16","author":"Lassmann","year":"2009","journal-title":"Endocr. Relat. Cancer."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1089\/thy.2014.0616","article-title":"Validation of a Simple Thyroid Cancer Dosimetry Model Based on the Fractional Whole-Body Retention at 48 Hours Post-Administration of 131I","volume":"25","author":"Atkins","year":"2015","journal-title":"Thyroid"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1021\/acs.molpharmaceut.3c00073","article-title":"Theranostic Surrogacy of [123I]NaI for Differentiated Thyroid Cancer Radionuclide Therapy","volume":"20","author":"Lee","year":"2023","journal-title":"Mol Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1097\/RLU.0000000000003464","article-title":"123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer","volume":"46","author":"Durski","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Brown, S.R., Hall, A., Buckley, H.L., Flanagan, L., de Castro, D.G., Farnell, K., Moss, L., Gregory, R., Newbold, K., and Du, Y. (2019). Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): Protocol for a multicentre UK single arm phase II trial. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5541-4"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","article-title":"European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer","volume":"35","author":"Luster","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e210046","DOI":"10.1530\/ETJ-21-0046","article-title":"2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?","volume":"11","author":"Pacini","year":"2022","journal-title":"Eur. Thyroid. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1089\/thy.2011.0203","article-title":"The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer","volume":"22","author":"Chen","year":"2012","journal-title":"Thyroid"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1089\/thy.2008.0419","article-title":"The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer","volume":"19","author":"Aiken","year":"2009","journal-title":"Thyroid"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/RLU.0000000000002246","article-title":"Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management","volume":"43","author":"Song","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_32","first-page":"632","article-title":"Comparison of 123I and 131I for whole-body imaging in thyroid cancer","volume":"43","author":"Sarkar","year":"2002","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003072-200101000-00002","article-title":"Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer","volume":"26","author":"Mandel","year":"2001","journal-title":"Clin. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2265.2001.01376.x","article-title":"The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: Avoidance of negative therapeutic uptake due to stunning","volume":"55","author":"Siddiqi","year":"2001","journal-title":"Clin. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1210\/jcem.86.11.8030","article-title":"123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: Comparison with post 131I therapy whole body scanning","volume":"86","author":"Alzahrani","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/RLU.0b013e3181b7dbb1","article-title":"A comparison between diagnostic I-123 and posttherapy I-131 scans in the detection of remnant and locoregional thyroid disease","volume":"34","author":"Thomas","year":"2009","journal-title":"Clin. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00006231-200402000-00006","article-title":"Clinical implications of the differences between diagnostic 123I and post-therapy 131I scans","volume":"25","author":"Cohen","year":"2004","journal-title":"Nucl. Med. Commun."},{"key":"ref_38","first-page":"320","article-title":"Clinical significance of discordant findings between pre-therapy 123I and post-therapy 131I whole body scan in patients with thyroid cancer","volume":"6","author":"Goudarzi","year":"2013","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s12149-009-0303-z","article-title":"Comparisons of I-123 diagnostic and I-131 post-treatment scans for detecting residual thyroid tissue and metastases of differentiated thyroid cancer","volume":"23","author":"Iwano","year":"2009","journal-title":"Ann. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s00259-006-0341-x","article-title":"Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: A comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement","volume":"34","author":"Urhan","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol Imaging"},{"key":"ref_41","first-page":"244","article-title":"Neck and whole-body scanning with 5-mCi dose of 123I as diagnostic tracer in patients with well-differentiated thyroid cancer","volume":"7","author":"Gulzar","year":"2001","journal-title":"Endocr. Pract."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00259-002-0781-x","article-title":"Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer","volume":"29","author":"Oei","year":"2002","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/01.mnm.0000194397.20067.b6","article-title":"The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy","volume":"27","author":"Ali","year":"2006","journal-title":"Nucl. Med. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1089\/thy.2014.0521","article-title":"The Use of 123I in Diagnostic Radioactive Iodine Scans in Children with Differentiated Thyroid Carcinoma","volume":"25","author":"Schoelwer","year":"2015","journal-title":"Thyroid"},{"key":"ref_45","first-page":"279","article-title":"The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases","volume":"27","author":"Yaakob","year":"1999","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4158\/EP.4.1.11","article-title":"Use of iodine-123 as a diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer","volume":"4","author":"Berbano","year":"1998","journal-title":"Endocr Pract."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s40618-019-01044-3","article-title":"Surveillance of patients with differentiated thyroid cancer and indeterminate response: A longitudinal study on basal thyroglobulin trend","volume":"42","author":"Malandrino","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Campenn\u00ec, A., Ruggeri, R.M., Siracusa, M., Romano, D., Giacoppo, G., Croc\u00e8, L., Rosarno, H., Russo, S., Cardile, D., and Capoccetti, F. (2023). Thyroglobulin Value Predict Iodine-123 Imaging Result in Differentiated Thyroid Cancer Patients. Cancers, 15.","DOI":"10.3390\/cancers15082242"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13044-021-00114-0","article-title":"Undetectable thyroglobulin makes 123I whole-body scan and stimulated thyroglobulin obsolete in follow-up care of differentiated thyroid cancer: A retrospective study","volume":"14","author":"Sol","year":"2021","journal-title":"Thyroid. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12020-021-02737-7","article-title":"Usefulness of 123I-spect\/ct to assess the response to initial therapy in differentiated thyroid cancer patients","volume":"74","author":"Vrachimis","year":"2021","journal-title":"Endocrine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/MNM.0000000000000922","article-title":"Usefulness of iodine-123 whole-body scan in planning iodine-131 treatment of the differentiated thyroid carcinoma in children and adolescence","volume":"39","author":"Villani","year":"2018","journal-title":"Nucl. Med. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/jc.2013-3156","article-title":"Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: A meta-analysis","volume":"99","author":"Giovanella","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e220312","DOI":"10.1530\/EC-22-0312","article-title":"Predictive value of highly sensitive basal versus stimulated thyroglobulin measurement in long-term follow-up of thyroid cancer","volume":"12","author":"Pabst","year":"2023","journal-title":"Endocr. Connect."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.beem.2017.04.010","article-title":"Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer","volume":"31","author":"Verburg","year":"2017","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.3390\/curroncol31070286","article-title":"Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer","volume":"31","author":"Volpe","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e33878","DOI":"10.1097\/MD.0000000000033878","article-title":"Clinical role of 18F-FDG PET\/CT for detection of radioactive iodine refractory differentiated thyroid cancer","volume":"102","author":"Tang","year":"2023","journal-title":"Medicine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s00259-007-0660-6","article-title":"Thediagnostic value of 124I-PET in patients with differentiated thyroid cancer","volume":"35","author":"Phan","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_58","first-page":"536","article-title":"The effectiveness of 124I-PET\/CT in patients with differentiated thyroid cancer","volume":"53","author":"Capoccetti","year":"2009","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_59","first-page":"213","article-title":"124-I PET\/CT images of differentiated thyroid cancer patients","volume":"51","author":"Nagarajah","year":"2012","journal-title":"Nuklearmedizin"},{"key":"ref_60","first-page":"15N","article-title":"SNMMI Procedure Standard\/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version","volume":"63","author":"Avram","year":"2022","journal-title":"J. Nucl. Med."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/68\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:26:56Z","timestamp":1770049616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/68"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medsci14010068"],"URL":"https:\/\/doi.org\/10.3390\/medsci14010068","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}